TipRanks
1 min read
In This Article:
Specialised Therapeutics announced the expansion of its existing supply and distribution agreement with Incyte (INCY) Biosciences International Sarl, the Swiss-based affiliate of Incyte, to launch and distribute two additional medicines from its oncology portfolio in Australia, New Zealand and Singapore, with an option to add further countries in the Asia-Pacific region. The expanded agreement will see new therapies axatilimab and retifanlimab added to the current partnered portfolio of Minjuvi and Pemazyre. Under the terms of the expanded agreement, Incyte will be responsible for the development, manufacture and supply of both axatilimab and retifanlimab to the region, while ST will have responsibility for regulatory, distribution and local marketing and medical affairs related activities. ST anticipates submitting axatilimab and retifanlimab for local regulatory and reimbursement approval in 2025.
-
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
-
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >;elm:context_link;itc:0;sec:content-canvas" href="https://thefly.com/?utm_source=finance.yahoo.com&utm_medium=referral" rel="nofollow noopener" target="_blank">Try Now>>
Read More on INCY:
Disclaimer & DisclosureReport an Issue
-
Incyte Stockholders Approve Key Amendments at Annual Meeting
-
Incyte’s Promising Pipeline and Strategic Developments Drive Buy Rating with $89 Price Target
-
Incyte’s Promising Drug Pipeline and INCA33989’s Strong Performance Drive Buy Rating
-
Incyte’s Mixed Clinical Trial Results and Uncertainties Lead to Hold Rating
-
Incyte’s Pipeline Developments: Balancing Promising Data with Uncertainties
